Differentiating acute Q fever from infections caused by other pathogens is essential. We conducted a retrospective case–control study to evaluate differences in clinical signs, symptoms, and outcomes for 82 patients with acute Q fever and 52 control patients who had pneumonia, fever and lower respiratory tract symptoms, or fever and hepatitis, but had negative serologic results for Q fever. Patients with acute Q fever were younger and had higher C-reactive protein levels but lower leukocyte counts. However, a large overlap was found. In patients with an indication for prophylaxis, chronic Q fever did not develop after patients received prophylaxis but did develop in 50% of patients who did not receive prophylaxis. Differentiating acute Q fever from other respiratory infections, fever, or hepatitis is not possible without serologic testing or PCR. If risk factors for chronic Q fever are present, prophylactic treatment is advised.

Q fever is a zoonosis caused by the bacterium *Coxiella burnetii*. During 2007–2010, the southern part of the Netherlands had the largest outbreak of Q fever ever reported (1,2). Infection with *C. burnetii* is symptomatic in ≈40% of all patients (3). Clinical signs range from a mild influenza-like illness to pneumonia or a hepatitis-like syndrome and can differ by region (4,5). After initial infection, chronic Q fever will develop in 1%–5% of patients (1,3). Furthermore, long-lasting fatigue will develop in ≈20% of all patients with symptomatic acute Q fever (6–8) without development of chronic Q fever (9).

Treatment for acute infection decreases the duration of fever, increases recovery from pneumonia (10), and might lead to a lower percentage of patients in whom chronic Q fever will develop (10–13). In addition, several reports indicate that, in acute Q fever patients at risk for development of chronic Q fever, prophylactic treatment might prevent persistent infection (12,14). Therefore, recognizing Q fever in an early stage is a useful strategy.

The only available data on symptoms of acute Q fever in the Netherlands were obtained from a retrospective study that collected data several months after onset of disease by sending questionnaires to patients with acute Q fever (15). However, this method for obtaining data is limited by a high risk for recall bias. To help physicians differentiate acute Q fever from other diseases, a clear description of signs and symptoms compatible with *C. burnetii* infection is desirable.

The purpose of this case–control study was to evaluate differences in clinical signs and symptoms between patients with acute Q fever referred to a hospital and a control group of patients with signs and symptoms that led to addition of Q fever in the differential diagnosis. Furthermore, outcome of patients hospitalized with acute Q fever were evaluated, and the effect of prophylactic treatment for those patients with an indication to prevent development of chronic Q fever was analyzed.

Materials and Methods

Patients

The study group consisted of adult patients who came to the Radboud university medical center or Canisius Wilhelmina Hospital in Nijmegen, the Netherlands, during January 2007–March 2011 with pneumonia, fever and lower respiratory tract symptoms, or fever and hepatitis, and who were given a diagnosis of acute Q fever. Symptoms had to be present for <3 weeks before presentation. Exclusion criteria were chronic Q fever and a known previous acute Q fever episode. The same clinical criteria were used for the control group, but Q fever serologic results and, if available, PCR results had to remain negative. A standardized case report form was completed for every patient. According
to national law, this study was exempt from approval by an ethics committee because of the retrospective characteristics of the study and the anonymous storage of data.

**PCR and Serologic Analysis**

During January 2007–March 2011, several laboratory techniques were used to diagnose acute Q fever. Because both hospitals collaborate extensively, the same microbiological laboratory techniques were used in both hospitals. The PCR used to detect DNA of *C. burnetii* in serum was an in-house, real-time PCR directed against insertion sequence IS1111a.

Serologic analysis was performed for blood samples by using the *Coxiella burnetii* (Q Fever) IgM ELISA (PanBio Pty Ltd., Windsor, Queensland, Australia), which detects IgM against phase II antigens and has a cutoff index of 1.1; a complement fixation assay (CFA) (Virion-Serion, Würzburg, Germany), which detects *C. burnetii* phase II antigens and shows a positive result if the titer is >1:10; and a Q fever immunofluorescent assay (IFA) for IgG and IgM (Focus Diagnostics Inc., Cypress, CA, USA), which detects IgM and IgG against phase I and phase II antigens and shows a positive result if the titer is >1:16.

**Definition of Acute Q Fever**

On the basis of the algorithm published by the Dutch working group on diagnostics of acute Q fever (16), the following definition of acute Q fever was used for all included patients: pneumonia, lower respiratory tract symptoms and fever, or hepatitis-like symptoms and fever, all ≤3 weeks before presentation; and 1) a positive serum PCR result ≤21 days of onset of disease; or 2) a negative serum PCR result, but a positive ELISA result for IgM against phase II antigens of *C. burnetii* and a positive CFA result for IgM and IgG against phase I and phase II antigens of *C. burnetii*; or 3) a negative serum PCR result but a positive ELISA result and a positive IFA result for IgM and IgG against phase II antigens of *C. burnetii*; or 4) two serum samples tested by CFA or IFA during an interval of ≥2 weeks that showed seroconversion or a 4-fold increase in titer.

A blood sample for Q fever serologic analysis obtained ≥2 weeks after the first day of illness was required because it was not possible to rule out acute Q fever if serologic samples are taken only at an earlier point, even if PCR results were negative during that period (16). Patients were selected only if an appropriate diagnostic procedure for Q fever was performed.

**Treatment**

Adequate treatment for acute Q fever was defined as antimicrobial drug therapy with doxycycline (200 mg/d), moxifloxacin (400 mg 1×/d), or ciprofloxacin (500 mg 2×/d) for ≥14 days (17,18). Indications for prophylactic treatment to prevent development of chronic Q fever were patients who met the criteria for endocarditis prophylaxis according to the international guidelines of the American Heart Association (19); patients with a structural aortic valve defect or mitral valve defect (12); patients with a known aneurysm of the aorta or other large vessels; and patients with a vascular prosthesis. Adequate prophylactic treatment was defined as doxycycline (200 mg/d) and hydroxychloroquine (200 mg 3×/d) for ≥6 months.

**Statistical Methods**

All data were analyzed by using SPSS version 20.0 (IBM, Armonk, NY, USA). For analysis of qualitative data, the Pearson’s χ² test was used. To evaluate the effect of prophylactic treatment, the Barnard exact test was used because this test is more powerful than the Fisher exact test for instances of smaller sample sizes (20). For quantitative data, the Student t-test was used. A p value <0.05 was considered significant.

**Results**

**General Characteristics**

A total of 82 patients with acute Q fever who fulfilled inclusion criteria for the study group and 52 patients who fulfilled criteria for the control group were included in the study (Table 1). Patients with acute Q fever were younger (mean ± SD age 52 ± 16 years vs. 59 ± 16 years; p = 0.03); had less often a history of lung disease (p = 0.001); and were immunocompromised less often (p = 0.002). Patients with acute Q fever had more history of smoking (p = 0.01) and a higher frequency of a sore throat (p = 0.008) (Table 2). Production of sputum was reported less frequently by patients with acute Q fever (p = 0.049).

**Physical Examination**

Of patients with acute Q fever, 18% had shortness of breath (Table 3) compared with 44% in the control group (p = 0.03). A total of 4% of patients with acute Q fever had rhonchi at pulmonary examination compared with 22% in the control group (p = 0.005). Oxygen saturation was significantly higher in patients with acute Q fever (p = 0.02).

**Laboratory Values**

Patients with acute Q fever had a higher levels of C-reactive protein (mean 167 mg/L vs. 117 mg/L; p = 0.02) (Table 4) and lower leukocyte counts (mean 9.0 × 10⁶ cells/L vs. 11.5 × 10⁶ cells/L; p = 0.006). Leukocyte counts remained significantly lower in the first 3 days after presentation (p = 0.006–0.043). At admission to the hospital, no differences were found between the groups for levels of alkaline phosphatase and γ-glutamyl transpeptidase. However, from day 1 onward, levels of alkaline
phosphatase and γ-glutamyl transpeptidase were significantly higher in patients with acute Q fever (p = 0.01–0.047 and p = 0.007–0.05, respectively).

**Table 1. Characteristics for patients with acute Q fever and control group with negative serologic results for Q fever, the Netherlands**

| Characteristic                                | Study group | Control group | p value  |
|-----------------------------------------------|-------------|---------------|----------|
| No. patients                                  | 82          | 52            | NS†      |
| Male sex, no. (%)                             | 53 (65)     | 38 (73)       | NS‡      |
| Mean ± SD age, y (range)                      | 52 ± 16 (23–91) | 59 ± 16 (19–85) | 0.027†   |
| Mean no. days between first day of sickness and presentation | 5.5         | 5.4           | NS†      |
| History of lung disease                       | 8/78 (10)   | 16/51 (35)    | 0.001†   |
| Immunocompromised§                            | 5/81 (6)    | 13/51 (25)    | 0.002‡   |
| Valvular dysfunction                          | 8/82 (10)   | 3/52 (6)      | NS‡      |
| Valve prosthesis                              | 3/82 (4)    | 0/52 (0)      | NS‡      |
| Aneurysm                                      | 2/82 (2)    | 3/52 (6)      | NS‡      |
| Vascular prosthesis                          | 3/82 (4)    | 3/52 (6)      | NS‡      |
| Liver disease                                 | 1/82 (1)    | 1/52 (2)      | NS‡      |
| Malignancy                                    | 2/82 (2)    | 9/52 (17)     | 0.002‡   |
| Diabetes                                      | 9/82 (11)   | 7/52 (13)     | NS‡      |
| Contact with cattle                           | 29/47 (62)  | 8/20 (40)     | NS‡      |
| History of smoking                            | 58/74 (78)  | 25/44 (57)    | 0.013‡   |
| Alcohol use                                   | 17/44 (39)  | 12/27 (44)    | NS‡      |
| Illicit drugs                                 | 4/35 (11)   | 0/18 (0)      | NS‡      |
| Proton pump inhibitors¶                       | 13/82 (16)  | 22/52 (42)    | 0.001†   |
| Corticosteroids†                               | 5/82 (6)    | 10/51 (20)    | 0.017‡   |

*Values are no. positive/no. tested (%) unless otherwise indicated. NS, not significant.
†By Student t-test.
‡By χ² test.
§Also includes patients using corticosteroids.
¶Only medications that differed significantly between groups is shown.

**Table 2. Signs and symptoms for patients with acute Q fever and control group with negative serologic results for Q fever, the Netherlands**

| Characteristic | Study group, n = 82, no. positive/no. tested (%) | Control group, n = 52, no. positive/no. tested (%) | p value† |
|----------------|--------------------------------------------------|---------------------------------------------------|----------|
| Fever          |                                                   |                                                   | NS       |
| Chills         | 64/75 (85)                                        | 37/49 (76)                                        | NS       |
| Myalgia        | 31/42 (74)                                        | 16/19 (74)                                        | NS       |
| Night sweats   | 10/24 (42)                                        | 7/14 (39)                                         | NS       |
| Weight loss    | 11/26 (42)                                        | 7/14 (39)                                         | NS       |
| Chest pain     | 11/26 (42)                                        | 7/14 (39)                                         | NS       |
| Dyspnea        | 20/37 (57)                                        | 31/43 (72)                                        | NS       |
| Rhinorrhea     | 12/7 (8)                                          | 7/14 (39)                                         | NS       |
| Sore throat    | 5/9 (18)                                          | 1/7 (14)                                          | NS       |
| Cough          | 12/22 (53)                                        | 12/22 (53)                                        | NS       |
| Sputum production | 10/30 (32)                                      | 38/48 (79)                                        | NS       |
| Nausea         | 14/48 (29)                                        | 14/48 (29)                                        | NS       |
| Vomiting       | 17/47 (36)                                        | 10/39 (26)                                        | NS       |
| Abdominal pain | 9/51 (18)                                         | 6/33 (18)                                         | NS       |
| Diarrhea       | 9/50 (18)                                         | 4/36 (11)                                         | NS       |
| Headache       | 10/29 (32)                                        | 21/28 (76)                                        | NS       |
| Weakness       | 9/21 (43)                                         | 1/8 (9)                                           | NS       |
| Painful joints | 0/10 (0)                                          | 7/10 (7)                                          | NS       |
| Arthritis      | 0/10 (0)                                          | 7/10 (7)                                          | NS       |

*NS, not significant.
†By χ² test.

ELISA was performed on samples from 33 patients with acute Q fever and 18 patients in the control group. Blood samples were obtained from the study group at day 10 ± 8 of illness and from the control group at day 7 ± 6 of illness. Sensitivity of this ELISA was 61%.

CFA, which was performed for 81 patients in the study group at day 9 ± 19 of illness and for 52 patients in the control group at day 8 ± 6 of illness, showed a sensitivity of 22% (Table 5). A total of 57 patients were hospitalized, of whom 36 were given a diagnosis of acute Q fever during their hospitalization.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 21, No. 8, August 2015 1351

Table 3. Physical examination results for patients with acute Q fever and control group with negative serologic results for Q fever, the Netherlands*

| Characteristic                  | Study group, n = 82 | Control group, n = 52 | p value |
|--------------------------------|---------------------|-----------------------|---------|
| Dyspnea                        | 13/73 (18)          | 18/41 (44)            | 0.03†   |
| Abnormal heart sounds          | 1/80 (1)            | 0/51 (0)              | NS†     |
| Cardiac murmur                 | 11/80 (14)          | 4/50 (8)              | NS†     |
| Decreased breath sounds        | 6/78 (8)            | 7/46 (15)             | NS†     |
| Bronchial breath sounds        | 9/64 (14)           | 5/37 (14)             | NS†     |
| Crackles                       | 36/76 (47)          | 19/43 (44)            | NS†     |
| Rhonchi                        | 3/68 (4)            | 9/41 (22)             | 0.005†  |
| Palpable liver                 | 1/69 (1)            | 1/39 (3)              | NS†     |
| Palpable spleen                | 0/68 (0)            | 0/36 (0)              | NS†     |
| Exanthema                      | 2/9 (22)            | 0/6 (0)               | NS‡     |
| Lymphadenopathy                | 2/27 (7)            | 2/21 (10)             | NS‡     |
| Temperature, °C (no. patients) | 38.4 (67)           | 38.3 (48)             | NS‡     |
| Heart rate, beats/min (no. patients) | 93 (73)          | 91 (50)               | NS‡     |
| Systolic blood pressure, mm Hg, (no. patients) | 134 (73)    | 138 (49)              | NS‡     |
| Respiratory rate, breaths/ min (no. patients) | 25 (24)      | 25 (21)               | NS‡     |
| Saturation, % oxygenation (no. patients)§ | 97 (57)       | 95 (34)               | 0.022‡  |

*Values are no positive/no. tested (%) unless otherwise indicated. NS, not significant.
†By χ² test.
‡By Student t-test.
§Saturation without oxygen.

Imaging Studies
A total of 78% of chest radiographs for patients with acute Q fever showed signs of pneumonia. A total of 54% of chest radiographs for patients in the control group showed signs of pneumonia (p = 0.003) (Table 5).

Treatment
Treatment was started before a diagnosis was made. Significantly more patients with acute Q fever started treatment with doxycycline than patients in the control group (35% vs. 15%; p = 0.001) (Table 6). For 8 patients in the study group, the duration of antimicrobial drug treatment was unknown. Of the remaining 74 patients with acute Q fever, 34 (46%) patients were given adequate treatment. The mean ± SD follow-up time for patients given adequate treatment was 11.7 ± 5 months compared with 13.3 ± 9 months for patients given inadequate treatment.

Outcomes
Hospitalization (70% vs. 94%; p = 0.001), admission to an intensive care unit (4% vs. 18%; p = 0.002), and need for respiratory support (2% vs. 16%; p = 0.001) were less common for the study group than for the control group (Table 7). Also, duration of hospital stay was shorter for patients with acute Q fever (9 ± 7 days vs. 17 ± 15 days; p = 0.001). Accurate follow-up data were available for 59 of 82 patients with acute Q fever who had a mean ± SD follow-up of 12.8 ± 8.2 months. Chronic Q fever developed in 6 (10%) patients in the Q fever group.

Sixteen patients with acute Q fever met the criteria for prophylactic treatment to prevent development of chronic Q fever (Table 8). Indications were valvular dysfunction (n = 8); cardiac valve prosthesis (n = 3); aneurysm (n = 1); vascular prosthesis (n = 3, of whom 1 patient also had a cardiac valve prosthesis); and a new cardiac murmur (n = 2). Eight (50%) of these patients received prophylactic treatment. Proper follow-up data for development of chronic Q fever were available for 14 patients with an indication for prophylaxis. Chronic Q fever did not develop in any of the 8 patients who received prophylaxis. The other 6 patients with an indication for prophylaxis for whom follow-up serum samples were available did not receive prophylaxis because the indication for prophylaxis was not recognized by the treating physician. Chronic Q fever developed in 3 (50%) of these 6 patients (p = 0.02). In the group without an indication for prophylaxis, chronic Q fever developed in 3 (6%) patients. Six (11%) of 56 patients in the study group for whom these data were available reported long-lasting fatigue.

The mortality rate during a 12-month follow-up period was 6% for the study group compared with 19% for the control group (p = 0.02). None of the patients in the study group died during the episode of acute Q fever. Four patients in the study group died because of reasons unrelated to Q fever. One patient died of consequences of an infected vascular prosthesis caused by chronic Q fever, although adequate treatment was started after the diagnosis. In contrast, 2 patients in the control group died during initial hospitalization, 1 of a Mycoplasma sp. infection and 1 of pneumonia without a known causative agent. Eight patients in the control group died during follow-up. One of them died of a non-Hodgkin lymphoma and 1 of consequences of an Aspergillus sp. infection. For the other 6 patients who died, no detailed information was available.

A total of 49 control patients were given a diagnosis of pneumonia; for 38 of these patients, no causative agent was found. For the remaining 11 patients, causative agents were Pneumocystis jiroveci, Moraxella catarrrhalis, Legionella pneumophila, Chlamydia sp., Haemophilus influenzae.
Table 4. Laboratory values for patients with acute Q fever and control group with negative serologic results for Q fever, the Netherlands*

| Laboratory value                      | Study group, n = 82 | Control group, n = 52 | p value‡ |
|---------------------------------------|---------------------|-----------------------|----------|
| Hemoglobin, mmol/L; reference range: men 8.1–10.7 mmol/L, women 7.3–9.7 mmol/L | Day† | Mean | No. tested | Mean | No. tested | p value‡ |
| 0                                     | 8.3                 | 77                    | 8.0      | 51   | NS          |          |
| 1                                     | 7.4                 | 28                    | 7.3      | 34   | NS          |          |
| 2–3                                   | 7.7                 | 27                    | 7.0      | 29   | 0.036       |          |
| 4–6                                   | 7.6                 | 27                    | 7.0      | 29   | NS          |          |
| Leukocytes, × 10⁹ cells/L; reference range 3.5–11.0 × 10⁹ cells/L | Day† | Mean | No. tested | Mean | No. tested | p value‡ |
| 0                                     | 9.0                 | 80                    | 11.5     | 50   | 0.006       |          |
| 1                                     | 8.5                 | 40                    | 10.8     | 28   | 0.043       |          |
| 2–3                                   | 8.0                 | 34                    | 11.1     | 33   | 0.021       |          |
| 4–6                                   | 10.9                | 28                    | 9.2      | 31   | NS          |          |
| Platelets, × 10⁹/L; reference range 20–350 × 10⁹/L | Day† | Mean | No. tested | Mean | No. tested | p value‡ |
| 0                                     | 239                 | 78                    | 208      | 50   | NS          |          |
| 1                                     | 242                 | 23                    | 178      | 29   | 0.038       |          |
| 2–3                                   | 229                 | 19                    | 172      | 26   | 0.042       |          |
| 4–6                                   | 298                 | 24                    | 208      | 27   | 0.011       |          |
| Total bilirubin, μmol/L; reference value <17 μmol/L | Day† | Mean | No. tested | Mean | No. tested | p value‡ |
| 0                                     | 14                  | 26                    | 16       | 20   | NS          |          |
| 1                                     | 12                  | 14                    | 14       | 8    | NS          |          |
| 2–3                                   | 9                   | 12                    | 28       | 6    | 0.017       |          |
| 4–6                                   | 8                   | 12                    | 9        | 6    | NS          |          |
| AP, U/L; reference value <120 U/L     | Day† | Mean | No. tested | Mean | No. tested | p value‡ |
| 0                                     | 104                 | 75                    | 85       | 50   | NS          |          |
| 1                                     | 127                 | 19                    | 75       | 12   | 0.047       |          |
| 2–3                                   | 126                 | 26                    | 66       | 12   | 0.010       |          |
| 4–6                                   | 145                 | 23                    | 95       | 15   | 0.036       |          |
| ALT, U/L; reference value <45 U/L     | Day† | Mean | No. tested | Mean | No. tested | p value‡ |
| 0                                     | 45                  | 76                    | 37       | 49   | NS          |          |
| 1                                     | 64                  | 22                    | 58       | 16   | NS          |          |
| 2–3                                   | 66                  | 30                    | 40       | 13   | 0.050       |          |
| 4–6                                   | 81                  | 22                    | 84       | 18   | NS          |          |
| γ-GT, U/L; reference value: men <50 U/L, women <35 U/L | Day† | Mean | No. tested | Mean | No. tested | p value‡ |
| 0                                     | 74                  | 68                    | 65       | 49   | NS          |          |
| 1                                     | 117                 | 21                    | 53       | 12   | 0.030       |          |
| 2–3                                   | 106                 | 27                    | 42       | 9    | 0.007       |          |
| 4–6                                   | 112                 | 22                    | 66       | 14   | 0.050       |          |
| CRP, mg/L; reference value <10 mg/L   | Day† | Mean | No. tested | Mean | No. tested | p value‡ |
| 0                                     | 187                 | 79                    | 117      | 50   | 0.015       |          |
| 1                                     | 184                 | 44                    | 150      | 37   | NS          |          |
| 2–3                                   | 132                 | 46                    | 147      | 32   | NS          |          |
| 4–6                                   | 76                  | 41                    | 98       | 27   | NS          |          |
| Urea, mmol/L; reference value 2.5–7 mmol/L | Day† | Mean | No. tested | Mean | No. tested | p value‡ |
| 0                                     | 6.4                 | 79                    | 8.6      | 51   | 0.039       |          |
| 1                                     | 6.4                 | 33                    | 7.9      | 35   | NS          |          |
| 2–3                                   | 5.4                 | 38                    | 8.7      | 35   | 0.014       |          |
| 4–6                                   | 5.8                 | 34                    | 9.3      | 30   | 0.018       |          |
| Creatinine, μmol/L; reference value: men <110 μmol/L, women <90 μmol/L | Day† | Mean | No. tested | Mean | No. tested | p value‡ |
| 0                                     | 86                  | 80                    | 105      | 52   | 0.042       |          |
| 1                                     | 84                  | 38                    | 103      | 38   | NS          |          |
| 2–3                                   | 79                  | 37                    | 103      | 37   | NS          |          |
| 4–6                                   | 81                  | 36                    | 136      | 31   | NS          |          |

*NS, not significant; AP, alkaline phosphatase; ALT, alanine aminotransferase; γ-GT, γ-glutamyl transpeptidase; CRP, C-reactive protein.
†Day 0 is the day of coming to the hospital.
‡By Student t-test.

(2 patients), Mycoplasma sp. (3 patients), influenza virus and Mycoplasma sp., and Staphylococcus aureus and Streptococcus pneumonia. The remaining 3 patients were given diagnoses of acute myeloid leukemia, non-Hodgkin lymphoma, and restrictive pericarditis.

Discussion

This retrospective case–control study evaluated differences in clinical signs and symptoms between patients with acute Q fever referred to a hospital and a control group. Because patients in the control group had Q fever included in the differential diagnosis, a selection bias is possible. However, differences were found between the 2 groups. In addition, because of the Q fever outbreak during that time, C. burnetii was considered a possible etiologic agent in many patients who came to a hospital. The higher number of patients in the study group can be explained by strict implementation of inclusion criteria for the control group.

Consistent with findings of earlier studies (1,27), we found that patients with acute Q fever more often had a history of smoking. However, a history of lung disease was found less often. A lower mean age in the study group than in the control group might explain this finding. Previous studies suggest typical signs and symptoms of acute Q fever: fever, headache, and cough (1,3,22). However, no difference was observed in the occurrence of fever. It has been postulated that headache is rather specific for acute Q fever (5,23). However, in our study, headache was less common in patients with acute Q fever than in the control group. Although cough was a relatively common sign in both groups, sputum...
production was reported less often in patients with acute Q fever. In addition, a sore throat was reported more often in the study group, which has not been previously reported.

A limitation of these results is the retrospective nature of the study because physicians probably did not include all signs and symptoms in patient charts. In general, patients with lung disease often use corticosteroids, which might explain why fewer patients in the study group were classified as immunocompromised. In contrast to medical and physical examination results, more patients with acute Q fever showed signs of an infiltrate on chest radiographs than when they came to the hospital. Although acute Q fever usually is a relatively mild influenza-like disease, it has been reported that chest radiographs often shows signs of an infiltrate (24). Compared with our control group, fewer patients in the study group needed hospitalization, and duration of hospitalization was shorter. These findings might be explained by the lower mean age of patients with acute Q fever, assuming that they were in a more healthy condition. Furthermore, *C. burnetii* is known for its self-limiting character, in contrast to those of other pathogens found in the control group.

In the Netherlands, a Q fever hospitalization rate of 50% in 2007 was registered, which stabilized at ≈20% in later years (25). This rate is higher than that previously reported (2%-5%) (5). However, large variations in hospitalization rates for acute Q fever patients have been reported (26). In this study, 70% of patients with acute Q fever were hospitalized. Most patients with acute Q fever are asymptomatic or have only a mild influenza-like illness. Thus, a selection bias caused by the study design is likely.

### Table 5. PCR and serologic results for patients in study group with acute Q fever and control group with negative serologic results for Q fever, the Netherlands*

| Characteristic     | Study group, n = 82 | Control group, n = 52 | Day of illness for study group, mean ± SD | Day of illness for control group, mean ± SD | Sensitivity, % |
|--------------------|---------------------|-----------------------|------------------------------------------|--------------------------------------------|---------------|
| PCR                |                     |                       |                                          |                                            |               |
| First sample       | 23/41 (28)          | 0/15 (0)              | 8 ± 7                                    | 8 ± 7                                      | 56            |
| Second sample      | 1/4 (1)             | 0/1 (0)               | 12 ± 5                                   | 30 ± 0                                     | 25            |
| ELISA              |                     |                       |                                          |                                            |               |
| First sample       | 20/33 (25)          | 0/18 (0)              | 10 ± 8                                   | 7 ± 6                                      | 61            |
| Second sample      | 15/18 (19)          | 0/2 (0)               | 20 ± 11                                  | 25 ± 8                                     | 83            |
| CFA                |                     |                       |                                          |                                            |               |
| First sample       | 18/81 (22)          | 0/52 (0)              | 9 ± 19                                   | 8 ± 6                                      | 22            |
| Second sample      | 27/34 (33)          | 0/28 (0)              | 18 ± 9                                   | 20 ± 12                                    | 79            |
| Third sample       | 5/5 (6)             | 0/3 (0)               | 21 ± 6                                   | 26 ± 5                                     | 100           |
| Culture            |                     |                       |                                          |                                            |               |
| Blood†             | 0/42 (0)            | 0/40 (0)              | NA                                       | NA                                         | NA            |
| Urine†             | 0/30 (0)            | 0/37 (0)              | NA                                       | NA                                         | NA            |
| Sputum‡            | 1/15 (7)            | 3/22 (14)             | NA                                       | NA                                         | NA            |
| Chest radiograph§  | 62/79 (78)          | 28/52 (54)            | NA                                       | NA                                         | 100           |

*Values are no. positive/no. tested (%) unless otherwise indicated. CFA, complement fixation assay; NA, not applicable.
†Includes only results for first cultures obtained after coming to the hospital.
‡Includes only first chest radiographs after coming to the hospital. Values are no. abnormal/no. tested (%).
¶Includes only results for first cultures obtained after coming to the hospital. In the study group, 1 patient was positive for parainfluenza virus. In the control group, 1 patient was positive for *Moraxella catarrhalis*, 1 patient was positive for *Legionella pneumophila*, and 1 patient was positive for *Streptococcus pneumonia* and *Staphylococcus aureus*.
§Includes only first chest radiographs after coming to the hospital. Values are no. abnormal/no. tested (%).

t<sub>p</sub> = 0.003, by χ<sup>2</sup> test.

### Table 6. Initial treatment for patients with acute Q fever and control group with negative serologic results for Q fever, the Netherlands*

| Initial treatment | Study group, n = 82, no. | Control group, n = 52, no. | p value† |
|-------------------|--------------------------|---------------------------|----------|
|                   | positive/no. tested (%)  | positive/no. tested (%)   |          |
| Doxycycline       | 29/82 (35)               | 8/52 (15)                 | 0.001    |
| Moxifloxacin      | 5/82 (6)                 | 2/52 (4)                  | NS       |
| Ciprofloxacin     | 7/82 (9)                 | 6/52 (12)                 | NS       |
| Penicillin        | 7/82 (9)                 | 1/52 (2)                  | 0.049    |
| Amoxicillin       | 13/82 (16)               | 5/52 (10)                 | NS       |
| Amoxicillin/clavulanic acid | 3/82 (4) | 4/52 (8) | NS       |
| Piperacillin/tazobactam | 1/82 (1) | 5/52 (10) | NS       |
| Cephalosporin     | 14/82 (17)               | 17/52 (33)                | NS       |
| Co-trimoxazole    | 0/82 (0)                 | 1/52 (2)                  | NS       |
| Fluoroaxcin       | 2/82 (2)                 | 0/52 (0)                  | NS       |
| Clarithromycin    | 0/82 (0)                 | 1/52 (2)                  | NS       |
| No treatment      | 1/82 (1)                 | 1/52 (2)                  | NS       |
| Unknown           | 0/82 (0)                 | 1/52 (2)                  | NS       |
| Patients with adequate treatment‡ | 34/74 (46) | NA | NA       |

*NS, not significant; NA, not applicable.
†By χ<sup>2</sup> test.
‡Defined as use of doxycycline (200 mg/d), moxifloxacin (400 mg 1×/d), or ciprofloxacin (500 mg 2×/d) for ≥2 wk.
We found that 78% of patients in the study group had an abnormal result on a chest radiograph, which might indicate that only patients with severe symptoms were hospitalized.

Although C-reactive protein levels and leukocyte counts differed between the study group and the control group, this finding did not contribute to differentiation between *C. burnetii* and other pathogens at hospitalization because differences were small and showed much overlap. In addition, although leukocyte counts were usually within the reference range, patients with acute Q fever more often had a lower leukocyte count, which is consistent with results of other studies (3,4). In contrast to these studies, which found thrombocytopenia in patients with acute Q fever, we found slightly higher levels of platelets, all within the reference range, in the study group than in the control group. Increased levels of liver enzymes have been reported in patients with acute Q fever (3,5,22). However, we found no differences in these levels between both groups at hospitalization. Furthermore, creatinine levels were not increased, in contrast to results reported in a previous study (3).

Although antimicrobial drug treatment was inadequate in an unexplainably high percentage of patients with acute Q fever, more patients in the study group than in the control group were initially treated with doxycycline, the treatment of choice for patients with acute Q fever. The choice of antimicrobial drug treatment in patients with community-acquired pneumonia (CAP) of unknown origin in the Netherlands depends on the Confusion, Urea nitrogen level in blood, Respiratory rate, Blood pressure, age ≥65 years (CURB-65) score (27). In addition, although CURB-65 scores could not be calculated for all patients, fewer patients in the study group were hospitalized, needed admission to an intensive care unit, and needed respiratory support, which suggests lower CURB-65 scores in the study group than in the control group.

Although changes were made in the national guidelines for treating CAP issued by the Dutch Working Party on Antibiotic Policy in 2011 (28), until 2011, doxycycline was the first choice for patients with a low CURB-65 score (29). In addition, more patients in the study group were given a diagnosis of having an infiltrate, which suggested that initial treatment in the study group was also aimed at atypical microorganisms. Presumably, patients in the control group were treated with broader spectrum antimicrobial drugs because of higher CURB-65 scores. Also, more patients in the control group were immunocompromised, which also could have influenced the choice of treatment.

Long-term prophylactic treatment with doxycycline and hydroxychloroquine has been suggested for patients with risk factors for development of chronic Q fever (12,14). Although controversy still exists (e.g., with regard to treatment duration and patient selection), prophylactic treatment of high-risk patients after an episode of acute Q fever can be beneficial and is widely advised (30–32). In our study, not all patients who had an indication according to our definition received prophylaxis. Chronic Q fever developed in 3 of 6 patients who did not receive prophylaxis, in contrast to none of the patients who received prophylaxis, which is a difference that clearly supports findings of other studies in which prophylactic treatment was suggested to prevent development of chronic Q fever in patients with risk factors for this disease (12,14). On the basis of these results, prophylactic treatment is advised if risk factors for developing chronic Q fever exist, but potential side effects must be taken into consideration (33).

For 48 of 67 patients without indication for prophylactic treatment, follow-up data were available on development of

---

**Table 7.** Outcome, follow-up, and prophylaxis for patients with acute Q fever and control group with negative serologic results for Q fever, the Netherlands*

| Characteristic                  | Study group | Control group | p value  |
|--------------------------------|-------------|---------------|----------|
| **Outcome**                    |             |               |          |
| Hospitalized                   | 57/82 (70)  | 49/52 (94)    | 0.001†   |
| Need for ICU                   | 2/57 (4)    | 9/49 (18)     | 0.002†   |
| Need for respiratory support   | 1/57 (2)    | 8/49 (16)     | 0.001†   |
| Mean ± SD duration of hospitalization, d | 9 ± 7       | 17 ± 15       | 0.001‡   |
| Mean ± SD duration of time in ICU, d | 5 ± 1       | 14 ± 10       | 0.266‡   |
| **Follow up**                  |             |               |          |
| Development of chronic Q fever | 6/59 (10)   | NA            | NA       |
| Development of long-lasting fatigue§ | 6/56 (11)  | NA            | NA       |
| Death                          | 5/82 (6)    | 10/52 (19)    | 0.019†   |
| Q fever–related death          | 1/82 (1)†   | NA            | NA       |
| **Indication for prophylaxis** |             |               |          |
| Development of chronic Q fever |             |               |          |
| Prophylactic treatment         | 0/8 (0)     | NA            | NA       |
| No prophylactic treatment      | 3/6 (50)    | NA            | 0.018‡   |

*Values are no. positive/no. tested (%) unless otherwise indicated. ICU, intensive care unit; NA, not applicable.
†By χ² test.
‡By Student t-test.
§Defined as persisting fatigue for >6 mo after acute Q fever in the absence of chronic Q fever.
¶This patient died of consequences of an infected vascular prosthesis caused by chronic Q fever.
#By unilateral Barnard exact test.

---

**RESEARCH**
Table 8. Characteristics of 16 patients with acute Q fever with an indication for prophylaxis, the Netherlands*

| Patient no. | Age, y/sex | Hospitalized | Indication at presentation for prophylactic treatment | Prophylactic treatment and duration, mo | Chronic Q fever | Died |
|-------------|------------|--------------|-----------------------------------------------------|----------------------------------------|----------------|------|
| 1           | 42/M       | Yes          | Valvular dysfunction (AS)                            | D + H, 12                              | No             | No   |
| 2           | 49/M       | Yes          | Cardiac bioprosthesis and vascular prosthesis        | D + H, 12                              | No             | No   |
| 3           | 51/M       | Yes          | Cardiac bioprosthesis and TOF                       | D 12 + H 4 (added after 8)             | No             | No   |
| 4           | 54/M       | Yes          | Aneurysm common iliac artery                         | D + H, 9                               | No             | No   |
| 5           | 43/M       | Yes          | Valvular dysfunction (TI) and TGV                    | D + H, 7                               | No             | No   |
| 6           | 78/F       | Yes          | Cardiac bioprosthesis                               | D + H, 1, switched to Mox, 3           | No             | Yes†|
| 7           | 26/M       | No           | Vascular prosthesis                                 | D + H, 2.5                             | No             | No   |
| 8           | 81/F       | Yes          | Valvular dysfunction (MI)                            | D + H, 12                              | No             | Yes‡|
| 9           | 65/M       | Yes          | Valvular dysfunction (MI)                            | No                                     | No             | No   |
| 10          | 80/M       | Yes          | Valvular dysfunction (MI)                            | No                                     | No             | No   |
| 11          | 78/F       | No           | Valvular dysfunction (MI)                            | No                                     | No             | No   |
| 12          | 64/F       | Yes          | Vascular prosthesis                                 | No                                     | Yes§           | No   |
| 13          | 75/F       | Yes          | New cardiac murmur                                   | No                                     | Yes            | No   |
| 14          | 75/M       | No           | New cardiac murmur                                   | No                                     | Yes            | No   |
| 15          | 57/F       | No           | Valvular dysfunction (AS)                            | No                                     | Unknown¶       | No   |
| 16          | 58/M       | Yes          | Valvular dysfunction (MI)                            | No                                     | Unknown¶       | No   |

*AS, aortic valve sclerosis; D, doxycycline 100 mg 2×/d; H, hydroxychloroquine 200 mg 3×/d; TOF, tetralogy of Fallot; TI, tricuspid insufficiency; TGV, transposition of the great vessels; Mox, moxifloxine 400 mg 1×/d; MI, mitral insufficiency; CFA, complement fixation assay; IFA, immunofluorescence assay.

†This patient was hospitalized shortly after the acute Q fever episode and died because of a reason unrelated to Q fever. The last available serologic follow-up showed no signs of chronic Q fever (negative PCR result; CFA titer 1:10; IFA IgG phase I titer 1:64; IgM phase II titer 1:84).

‡This patient eventually died because of a reason unrelated to Q fever. The last available serologic follow-up 1 year after the acute Q fever episode showed no signs of chronic Q fever (negative PCR result; CFA titer 1:10; IFA IgG phase I titer 1:64; IgG phase II titer 1:512; IgM phase I titer 1:16, and IgM phase II titer 1:16).

§This patient was hospitalized and admitted to the intensive care unit for 5 d. She was treated with several antimicrobial drugs (penicillin, ciprofloxacin, cefuroxim, metronidazol, ceftazidim, and teicoplanin) before given a diagnosis of an infected vascular prosthesis caused by chronic Q fever. Although doxycycline and hydroxychloroquine were given after the diagnosis was made, this patient eventually died from consequences of an infected vascular prosthesis caused by chronic Q fever.

¶No follow-up with reference to Q fever was performed for this patient.

chronic Q fever. Chronic Q fever developed in 3 (6%) of these patients, which is slightly higher than expected (1,34). This finding might be explained by the fact that we included only patients who were referred to a hospital, and therefore selected patients most affected by C. burnetii infection. It is possible that more severely acute Q fever predisposes for development of chronic Q fever (13).

After having acute Q fever, patients often report lasting fatigue, which frequently persists for >6 months. This symptom after acute Q fever has been designated Q fever fatigue syndrome. Our data suggest a prevalence of 11%, which is lower than expected; other studies reported a prevalence of ≈20% worldwide and a higher prevalence in the Netherlands (6,35,36). The prevalence found in this study is presumably an underestimation because proper analysis was not performed for most patients.

Although we found some differences in clinical manifestations for patients with acute Q fever coming to a hospital compared with controls, considerable overlap between both groups hamper the use of these variables for clinical differentiation. Differentiating C. burnetii from other pathogens is not possible without Q fever serologic analysis and PCR in patients coming to a hospital. In disease-endemic areas or in instances in which patients have risk factors for Q fever, suspicion should remain high, and the threshold for performing Q fever serologic analysis and PCR should remain low. Because only 46% of patients received adequate treatment acute Q fever in our study, treatment for acute Q fever should be improved. Furthermore, our findings underline the recommendation that prophylactic treatment should be given to patients with risk factors for developing chronic Q fever. However, more studies are needed to develop uniform guidelines with regard to optimal prophylactic treatment.

Acknowledgment

We thank Ton Dofferhoff for collecting data and treating several patients.

Mr. Keijmel is an MD/PhD candidate at the Radboud university medical center, Nijmegen, the Netherlands. His research activities focus on long-term consequences of Q fever.

References

1. Delsing CE, Kullberg BJ, Bleeker-Rovers CP. Q fever in the Netherlands from 2007 to 2010. Neth J Med. 2010;68:382–7.
2. Tilburg JJ, Rossen JW, van Hammen EJ, Melchers WJ, Hermans MH, van de Bovenkamp J, et al. Genotypic diversity of Coxiella burnetii in the 2007–2010 Q fever outbreak episodes in The Netherlands. J Clin Microbiol. 2012;50:1076–8. http://dx.doi.org/10.1128/JCM.05497-11
3. Maurin M, Raoult D. Q fever. Clin Microbiol Rev. 1999;12:518–53.
4. Fournier PE, Marrie TJ, Raoult D. Diagnosis of Q fever. J Clin Microbiol. 1998;36:1823–34.
5. Raoult D, Marrie T, Mege J. Natural history and pathophysiology of Q fever. Lancet Infect Dis. 2005;5:219–26. http://dx.doi.org/10.1016/S1473-3099(05)70052-9
6. Wildman MJ, Smith EG, Groves J, Beattie JM, Caul EO, Ayres JG. Chronic fatigue following infection by Coxiella burnetii (Q fever): ten-year follow-up of the 1989 UK outbreak cohort. QJM. 2002;95:527–38. http://dx.doi.org/10.1093/qjmed/95.8.527

7. Keijmel SP, Moroy G, Delsing CE, Bleijenberg G, Bleeker-Rovers CP, Timen A. Persistent fatigue following Q fever [in Dutch]. Ned Tijdschr Geneeskd. 2012;156:A2528.

8. Moroy G, Peters JB, van Nieuwenhof M, Bor HHJ, Huvastv JLA, van der Hoek W, et al. The health status of Q-fever patients after long-term follow-up. BMC Infect Dis. 2011;11:97. http://dx.doi.org/10.1186/1471-2334-11-97

9. The Dutch Working Group Q fever fatigue syndrome. Dutch guideline Q fever fatigue syndrome, 2012 [in Dutch] [cited 2015 Mar 31]. http://www.rivm.nl/Bibliotheek/Professioneel_Praaktisch/ Richtlijnen/Infectieziekten/LC1_richtlijnen/LC1_richtlijn_Q_koortsversmoeidheidssyndroom_QVS

10. Marrie TJ. Coxiella burnetii pneumonia. Eur Respir J. 2003;21:713–9. http://dx.doi.org/10.1183/09031936.03.0009703

11. Dijkstra F, Ripphagen-Dalhuisen J, Wijers N, Hak E, van der Sande MAB, Moroy G, et al. Antibiotic therapy for acute Q fever in The Netherlands in 2007 and 2008 and its relation to hospitalization. Epidemiol Infect. 2011;139:1332–41. http://dx.doi.org/10.1017/S0950268810006261

12. Fenollar F, Fournier PE, Carriere MP, Habib G, Messana T, Raoult D. Risks factors and prevention of Q fever endocarditis. Clin Infect Dis. 2001;33:312–6. http://dx.doi.org/10.1086/321889

13. Kampschreur LM, Dekker S, Hagenaars JC, Lestrade PJ, et al. Case-control study for risk factors for Q fever in southwest England and Northern Ireland. Euro Surveill. 2006;11:260–2.

14. Million M, Walter G, Thuny F, Habib G, Raoult D. Evolution from acute Q fever to endocarditis is associated with underlying valvulopathy and age and can be prevented by prolonged antibiotic treatment. Clin Infect Dis. 2013;57:836–44. http://dx.doi.org/10.1093/cid/cit149

15. Karagiannis I, Schimmer B, Van Lier A, Timen A, Schneeberger P, Renders NH, de Jager-Leclercq MG, et al. Identification of risk factors for chronic Q fever, the Netherlands. Emerg Infect Dis. 2012;18:563–70. http://dx.doi.org/10.3201/eid1804.111478

16. Million M, Walter G, Thuny F, Habib G, Raoult D. Evolution from acute Q fever to endocarditis is associated with underlying valvulopathy and age and can be prevented by prolonged antibiotic treatment. Clin Infect Dis. 2013;57:836–44. http://dx.doi.org/10.1093/cid/cit149

17. Spelman DW. Q fever: a study of 111 consecutive cases. Med J Aust. 1996;165:527–8, 551, 553.

18. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, et al. Prevention of infective endocarditis: guide lines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116:1736–54. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.183095

19. Mehta CR, Senchaudhuri P. Conditional versus unconditional exact tests for comparing two binomials. Cambridge (MA): Cytel Software Corporation; 2003 [cited 2015 Mar 31]. http://www.cytel.com/papers/twobinomials.pdf

20. Orr HJ, Christensen H, Smyth B, Dance DA, Carrington D, Paul I, et al. Case-control study for risk factors for Q fever in southwest England and Northern Ireland. Euro Surveill. 2006;11:260–2.

21. Orr HJ, Christensen H, Smyth B, Dance DA, Carrington D, Paul I, et al. Case-control study for risk factors for Q fever in southwest England and Northern Ireland. Euro Surveill. 2006;11:260–2.

22. Parker NR, Barralet JH, Bell AM. Q fever. Lancet. 2006;367:679–88. http://dx.doi.org/10.1016/S0140-6736(06)68266-4

23. Honarmand H. Q fever: an old but still a poorly understood disease. Interdiscip Perspect Infect Dis. 2012;2012:6131392. http://dx.doi.org/10.1155/2012/6131392

24. Delsing CE, Bleeker-Rovers CP, Nabuurs-Franssen M, Sprong T, van der Ven AJ, Kullberg BJ. Q fever, a potential serious disease [in Dutch]. Ned Tijdschr Geneeskd. 2009;153:652–7.

25. van der Hoek W, Dijkstra F, Schimmer B, Schneeberger PM, Velleman P, Wijkmans C, et al. Q fever in the Netherlands: an update on the epidemiology and control measures. Euro Surveill. 2010;15 pii: 19520.

26. Wielders CC, Waister AM, de Visser VL, de Jager-Leclercq MG, Groot CA, Dijkstra F, et al. Characteristics of hospitalized acute Q fever patients during a large epidemic, The Netherlands. PLoS ONE. 2014;9:e91764. http://dx.doi.org/10.1371/journal.pone.0091764

27. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–82. http://dx.doi.org/10.1136/thorax.58.5.377

28. Dutch Working Party on Antibiotic Policy. Guidelines for diagnosis and treatment of community-acquired pneumonia in adults, 2011 [cited 2015 Jun 3]. http://www.swab.nl/swab/cms3.nl/uploads/48/C3A8CABAEDAC7C8AC12578A782004798A7/SFILE/CAP_SWAB_concept150611.pdf

29. Schouten JA, Prins JM, Bonten MJ, Degener J, Janknegt RE, Hollander JM, et al. Revised SWAB guidelines for antimicrobial therapy of community-acquired pneumonia. Neth J Med. 2005;63:323–35.

30. Kampschreur LM, Oosterheert JJ, Weaver PC, Bleeker-Rovers CP. Antibiotic prophylaxis for high-risk patients with acute Q fever: no definitive answers yet. Clin Infect Dis. 2014;58:446–7. http://dx.doi.org/10.1093/cid/cit718

31. Limonard GJ, Nabuurs-Franssen MH, Weers-Pothoff G, Wijkman C, Besselink R, Horrevoets AM, et al. One-year follow-up of patients of the ongoing Dutch Q fever outbreak: clinical, serological and echocardiographic findings. Infection. 2010;38:471–7. http://dx.doi.org/10.1007/s15010-010-0052-x

32. van der Hoek W, Versteeg B, Meekeelenkamp JC, Rengers NH, Leenders AC, Weers-Pothoff I, et al. Follow-up of 686 patients with acute Q fever and detection of chronic infection. Clin Infect Dis. 2011;52:1431–6. http://dx.doi.org/10.1093/cid/cir234

33. Keijmel S, van Kasteren M, Bloks W, van der Meer J, van Rossum M, Bleeker-Rovers C. Cutaneous hyperpigmentation induced by doxycycline: a case series. Netherlands Journal of Medicine. 2015;73:37–40.

34. Wegdam-Blans MC, Kampschreur LM, Delsing CE, Bleeker-Rovers CP, Sprong T, van Kasteren ME, et al. Chronic Q fever: review of the literature and a proposal of new diagnostic criteria. J Infect. 2012;64:247–59. http://dx.doi.org/10.1016/j.jinf.2011.12.014

35. Marmion BP, Shannon M, Maddocks I, Storm P, Penttila I. Protracted debility and fatigue after acute Q fever. Lancet. 1996;347:977–8. http://dx.doi.org/10.1016/S0140-6736(96)91469-5

36. Limonard GJ, Nabuurs-Franssen MH, Weers-Pothoff G, Wijkman C, Besselink R, Horrevoets AM, et al. One-year follow-up of patients of the ongoing Dutch Q fever outbreak: clinical, serological and echocardiographic findings. Infection. 2010;38:471–7. http://dx.doi.org/10.1007/s15010-010-0052-x

Address for correspondence: Stephan P. Keijmel, Department of Internal Medicine/Division of Infectious Diseases 463, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, the Netherlands; email: stephan.keijmel@radboudumc.nl

1356 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 21, No. 8, August 2015